{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:29:35Z","timestamp":1782512975791,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","award":["WJ2023M004"],"award-info":[{"award-number":["WJ2023M004"]}],"id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"crossref","award":["YXJL-2023-0866-0329"],"award-info":[{"award-number":["YXJL-2023-0866-0329"]}],"id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IgA nephropathy (IgAN) is a common glomerular disease in children that may progress to chronic kidney disease (CKD) and kidney failure. Identifying reliable prognostic markers is important for guiding clinical management. This study investigated independent predictors of poor prognosis in pediatric IgAN and their impact on eGFR slope, as well as the dynamic patterns of complete kidney remission and relapse, predictive factors associated with remission, and the influence of remission on poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study of 224 children (aged 3\u201318\u00a0years) with biopsy-proven IgAN and\u2009\u2265\u20093\u00a0years of follow-up was enrolled. Poor prognosis was defined as persistent eGFR\u2009&lt;\u200990\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      for\u2009\u2265\u20093\u00a0months. Multivariate logistic regression, receiver operating characteristic (ROC) curve analysis, and linear mixed-effects model were used to identify predictive factors and evaluate eGFR slope. Complete kidney remission was defined as the absence of hematuria and proteinuria with eGFR\u2009\u2265\u200990\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      for\u2009\u2265\u20091\u00a0year. Cumulative incidence function and Fine-Gray competing risk regression model were applied to analyze remission dynamic patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median follow-up of 5.41\u00a0years, 12.05% reached the poor prognosis. Independent risk factors included male sex, older age at biopsy, Oxford classification E1 and S1 lesions, absence of gross hematuria, and no remission of proteinuria during follow-up, while higher birth weight was protective. eGFR slope was influenced by age at biopsy, gross hematuria and proteinuria remission status during follow-up. Complete kidney remission occurred in 70.98%, with a recurrence rate of 60.38%. Predictors of complete kidney remission included antecedent infection, kidney IgM deposition of 2\u2009+\u2009, elevated serum IgM, increased pathological casts count, and prednisone treatment, while prolonged disease duration before biopsy and higher tubular casts count were risk factors. Group comparisons and logistic regression analysis showed no significant associations between kidney remission and poor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pediatric IgAN shows slow disease progression over 5\u00a0years. Despite high complete kidney remission rates, recurrence remains common. These findings support extended follow-up and improved predictive models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-06988-8","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:26:29Z","timestamp":1762993589000},"page":"731-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognosis and predictive factors in pediatric IgA nephropathy"],"prefix":"10.1007","volume":"41","author":[{"given":"Wenpei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-7183","authenticated-orcid":false,"given":"Liru","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"6988_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.ajkd.2019.02.016","volume":"74","author":"T Chen","year":"2019","unstructured":"Chen T, Li X, Li Y et al (2019) Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am J Kidney Dis 74:300\u2013309. https:\/\/doi.org\/10.1053\/j.ajkd.2019.02.016","journal-title":"Am J Kidney Dis"},{"key":"6988_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/nep.13592","volume":"24","author":"SC Yeo","year":"2019","unstructured":"Yeo SC, Goh SM, Barratt J (2019) Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology 24:885\u2013895. https:\/\/doi.org\/10.1111\/nep.13592","journal-title":"Nephrology"},{"key":"6988_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00281-021-00884-7","volume":"43","author":"H Zhang","year":"2021","unstructured":"Zhang H, Barratt J (2021) Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol 43:707\u2013715. https:\/\/doi.org\/10.1007\/s00281-021-00884-7","journal-title":"Semin Immunopathol"},{"key":"6988_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00467-024-06361-1","volume":"39","author":"B Su","year":"2024","unstructured":"Su B, Jiang Y, Li Z et al (2024) Are children with IgA nephropathy different from adult patients? Pediatr Nephrol 39:2403\u20132412. https:\/\/doi.org\/10.1007\/s00467-024-06361-1","journal-title":"Pediatr Nephrol"},{"key":"6988_CR5","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40620-020-00725-0","volume":"33","author":"R Coppo","year":"2020","unstructured":"Coppo R, Robert T (2020) IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol 33:1219\u20131229. https:\/\/doi.org\/10.1007\/s40620-020-00725-0","journal-title":"J Nephrol"},{"key":"6988_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/cjn.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA Nephropathy. Clin J Am Soc Nephrol 12:677\u2013686. https:\/\/doi.org\/10.2215\/cjn.07420716","journal-title":"Clin J Am Soc Nephrol"},{"key":"6988_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-012-2294-6","volume":"28","author":"Y Shima","year":"2013","unstructured":"Shima Y, Nakanishi K, Hama T et al (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71\u201376. https:\/\/doi.org\/10.1007\/s00467-012-2294-6","journal-title":"Pediatr Nephrol"},{"key":"6988_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00467-020-04486-7","volume":"36","author":"R Coppo","year":"2021","unstructured":"Coppo R (2021) Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol 36:491\u2013496. https:\/\/doi.org\/10.1007\/s00467-020-04486-7","journal-title":"Pediatr Nephrol"},{"key":"6988_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","volume":"30","author":"R Coppo","year":"2017","unstructured":"Coppo R (2017) Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol 30:339\u2013346. https:\/\/doi.org\/10.1007\/s40620-016-0360-z","journal-title":"J Nephrol"},{"key":"6988_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00467-020-04475-w","volume":"36","author":"A Cambier","year":"2021","unstructured":"Cambier A, Gleeson PJ, Flament H et al (2021) New therapeutic perspectives for IgA nephropathy in children. Pediatr Nephrol 36:497\u2013506. https:\/\/doi.org\/10.1007\/s00467-020-04475-w","journal-title":"Pediatr Nephrol"},{"key":"6988_CR11","doi-asserted-by":"publisher","first-page":"1183562","DOI":"10.3389\/fped.2023.1183562","volume":"11","author":"X Yu","year":"2023","unstructured":"Yu X, Li J, Tao C et al (2023) Validation of the children international IgA nephropathy prediction tool based on data in Southwest China. Front Pediatr 11:1183562. https:\/\/doi.org\/10.3389\/fped.2023.1183562","journal-title":"Front Pediatr"},{"key":"6988_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","volume":"99","author":"SJ Barbour","year":"2021","unstructured":"Barbour SJ, Coppo R, Er L (2021) Updating the international IgA nephropathy prediction tool for use in children. Kidney Int 99:1439\u20131450. https:\/\/doi.org\/10.1016\/j.kint.2020.10.033","journal-title":"Kidney Int"},{"key":"6988_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.kint.2024.07.012","volume":"106","author":"SJ Barbour","year":"2024","unstructured":"Barbour SJ, Coppo R, Er L et al (2024) Application of the updated international IgA nephropathy prediction tool in children one or two years post-biopsy. Kidney Int 106:913\u2013927. https:\/\/doi.org\/10.1016\/j.kint.2024.07.012","journal-title":"Kidney Int"},{"key":"6988_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533\u2013569. https:\/\/doi.org\/10.1007\/s00467-024-06502-6","journal-title":"Pediatr Nephrol"},{"key":"6988_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7326\/m20-4366","volume":"174","author":"H Pottel","year":"2021","unstructured":"Pottel H, Bj\u00f6rk J, Courbebaisse M et al (2021) Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate\u202f: a cross-sectional analysis of pooled data. Ann Intern Med 174:183\u2013191. https:\/\/doi.org\/10.7326\/m20-4366","journal-title":"Ann Intern Med"},{"key":"6988_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3343\/alm.2023.0237","volume":"44","author":"H Pottel","year":"2024","unstructured":"Pottel H, Delanaye P, Cavalier E (2024) Exploring renal function assessment: creatinine, cystatin C, and estimated glomerular filtration rate focused on the European Kidney Function Consortium equation. Ann Lab Med 44:135\u2013143. https:\/\/doi.org\/10.3343\/alm.2023.0237","journal-title":"Ann Lab Med"},{"key":"6988_CR17","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ et al (2024) Kdigo 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"6988_CR18","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/asn.2019010008","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams ME, Sang Y, Ballew SH (2019) Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol 30:1746\u20131755. https:\/\/doi.org\/10.1681\/asn.2019010008","journal-title":"J Am Soc Nephrol"},{"key":"6988_CR19","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1681\/ASN.2019010009","volume":"30","author":"T Greene","year":"2019","unstructured":"Greene T, Ying J, Vonesh EF et al (2019) Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J Am Soc Nephrol 30:1756\u20131769. https:\/\/doi.org\/10.1681\/ASN.2019010009","journal-title":"J Am Soc Nephrol"},{"key":"6988_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H et al (2019) Gfr slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol 30:1735\u20131745. https:\/\/doi.org\/10.1681\/ASN.2019010007","journal-title":"J Am Soc Nephrol"},{"key":"6988_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11255-020-02631-7","volume":"53","author":"D Wen","year":"2021","unstructured":"Wen D, Tang Y, Tan L et al (2021) Sex disparities in IgA nephropathy: a retrospective study in Chinese patients. Int Urol Nephrol 53:315\u2013323. https:\/\/doi.org\/10.1007\/s11255-020-02631-7","journal-title":"Int Urol Nephrol"},{"key":"6988_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.medici.2016.11.003","volume":"52","author":"\u017d Riispere","year":"2016","unstructured":"Riispere \u017d, Laurinavi\u010dius A, Kuudeberg A et al (2016) IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences. Medicina (Kaunas) 52:340\u2013348. https:\/\/doi.org\/10.1016\/j.medici.2016.11.003","journal-title":"Medicina (Kaunas)"},{"key":"6988_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00467-016-3469-3","volume":"32","author":"R Coppo","year":"2017","unstructured":"Coppo R, Lofaro D, Camilla RR et al (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139\u2013150. https:\/\/doi.org\/10.1007\/s00467-016-3469-3","journal-title":"Pediatr Nephrol"},{"key":"6988_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1001\/archinte.160.10.1472","volume":"160","author":"DT Lackland","year":"2000","unstructured":"Lackland DT, Bendall HE, Osmond C et al (2000) Low birth weights contribute to high rates of early-onset chronic renal failure in the southeastern United States. Arch Intern Med 160:1472\u20131476. https:\/\/doi.org\/10.1001\/archinte.160.10.1472","journal-title":"Arch Intern Med"},{"key":"6988_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0140-6736(13)60311-6","volume":"382","author":"VA Luyckx","year":"2013","unstructured":"Luyckx VA, Bertram JF, Brenner BM et al (2013) Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 382:273\u2013283. https:\/\/doi.org\/10.1016\/s0140-6736(13)60311-6","journal-title":"Lancet"},{"key":"6988_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000044987","volume":"79","author":"N Zidar","year":"1998","unstructured":"Zidar N, Cavi\u0107 MA, Kenda RB et al (1998) Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron 79:28\u201332. https:\/\/doi.org\/10.1159\/000044987","journal-title":"Nephron"},{"key":"6988_CR27","doi-asserted-by":"publisher","first-page":"e0153819","DOI":"10.1371\/journal.pone.0153819","volume":"11","author":"P Ruggajo","year":"2016","unstructured":"Ruggajo P, Svarstad E, Leh S et al (2016) Low birth weight and risk of progression to end stage renal disease in IgA nephropathy\u2013a retrospective registry-based cohort study. PLoS One 11:e0153819. https:\/\/doi.org\/10.1371\/journal.pone.0153819","journal-title":"PLoS One"},{"key":"6988_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12882-018-1070-7","volume":"19","author":"P Ruggajo","year":"2018","unstructured":"Ruggajo P, Leh S, Svarstad E et al (2018) Low birth weight associates with glomerular area in young male IgA nephropathy patients. BMC Nephrol 19:287. https:\/\/doi.org\/10.1186\/s12882-018-1070-7","journal-title":"BMC Nephrol"},{"key":"6988_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ekir.2018.03.013","volume":"3","author":"A Cambier","year":"2018","unstructured":"Cambier A, Rabant M, Peuchmaur M et al (2018) Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3:916\u2013925. https:\/\/doi.org\/10.1016\/j.ekir.2018.03.013","journal-title":"Kidney Int Rep"},{"key":"6988_CR30","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00467-019-04414-4","volume":"35","author":"H Trimarchi","year":"2020","unstructured":"Trimarchi H, Coppo R (2020) The implications of focal segmental glomerulosclerosis in children with IgA nephropathy. Pediatr Nephrol 35:2043\u20132047. https:\/\/doi.org\/10.1007\/s00467-019-04414-4","journal-title":"Pediatr Nephrol"},{"key":"6988_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/ndt\/gfy302","volume":"35","author":"R Coppo","year":"2018","unstructured":"Coppo R, D\u2019arrigo G, Tripepi G et al (2018) Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant 35:1002\u20131009. https:\/\/doi.org\/10.1093\/ndt\/gfy302","journal-title":"Nephrol Dial Transplant"},{"key":"6988_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12882-020-01913-7","volume":"21","author":"H Wu","year":"2020","unstructured":"Wu H, Xia Z, Gao C et al (2020) The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study. BMC Nephrol 21:247. https:\/\/doi.org\/10.1186\/s12882-020-01913-7","journal-title":"BMC Nephrol"},{"key":"6988_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/nep.12850","volume":"21","author":"RCG Fabiano","year":"2016","unstructured":"Fabiano RCG, Pinheiro SVB, De Almeida Ara\u00fajo S et al (2016) Immunoglobulin a nephropathy: pathological markers of renal survival in paediatric patients. Nephrology 21:995\u20131002. https:\/\/doi.org\/10.1111\/nep.12850","journal-title":"Nephrology"},{"key":"6988_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40620-015-0227-8","volume":"29","author":"A Chakera","year":"2016","unstructured":"Chakera A, Macewen C, Bellur SS et al (2016) Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol 29:367\u2013375. https:\/\/doi.org\/10.1007\/s40620-015-0227-8","journal-title":"J Nephrol"},{"key":"6988_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jped.2016.09.003","volume":"93","author":"RCG Fabiano","year":"2017","unstructured":"Fabiano RCG, Ara\u00fajo SA, Bambirra EA et al (2017) The Oxford classification predictors of chronic kidney disease in pediatric patients with IgA nephropathy. J Pediatr (Rio J) 93:389\u2013397. https:\/\/doi.org\/10.1016\/j.jped.2016.09.003","journal-title":"J Pediatr (Rio J)"},{"key":"6988_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2411846","volume":"46","author":"X Liu","year":"2024","unstructured":"Liu X, Wang C, Sun Z et al (2024) Predictive role of Oxford classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis. Ren Fail 46:2411846. https:\/\/doi.org\/10.1080\/0886022X.2024.2411846","journal-title":"Ren Fail"},{"key":"6988_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/ndt\/gfr339","volume":"27","author":"S Edstr\u00f6m Halling","year":"2011","unstructured":"Edstr\u00f6m Halling S, S\u00f6derberg MP, Berg UB (2011) Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 27:715\u2013722. https:\/\/doi.org\/10.1093\/ndt\/gfr339","journal-title":"Nephrol Dial Transplant"},{"key":"6988_CR38","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/ndt\/gfy337","volume":"34","author":"SS Bellur","year":"2019","unstructured":"Bellur SS, Roberts ISD, Troyanov S et al (2019) Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort. Nephrol Dial Transplant 34:1681\u20131690. https:\/\/doi.org\/10.1093\/ndt\/gfy337","journal-title":"Nephrol Dial Transplant"},{"key":"6988_CR39","doi-asserted-by":"publisher","unstructured":"Coppo R, Fervenza FC (2017) Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker.\u00a0J Am Soc Nephrol 28:2831\u20132834.\u00a0https:\/\/doi.org\/10.1681\/ASN.2017060639","DOI":"10.1681\/ASN.2017060639"},{"key":"6988_CR40","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL (2024) Contemporary review of IgA nephropathy. Front Immunol 15:1436923. https:\/\/doi.org\/10.3389\/fimmu.2024.1436923","journal-title":"Front Immunol"},{"key":"6988_CR41","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.ekir.2024.03.003","volume":"9","author":"S Ishimori","year":"2024","unstructured":"Ishimori S, Horinouchi T, Yamamura T et al (2024) Role of iron in children with immunoglobulin A nephropathy and macrohematuria-induced acute kidney injury. Kidney Int Rep 9:1664\u20131673. https:\/\/doi.org\/10.1016\/j.ekir.2024.03.003","journal-title":"Kidney Int Rep"},{"key":"6988_CR42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/0886022X.2021.1879852","volume":"43","author":"P He","year":"2021","unstructured":"He P, Wang H, Huang C et al (2021) Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis. Ren Fail 43:488\u2013499. https:\/\/doi.org\/10.1080\/0886022X.2021.1879852","journal-title":"Ren Fail"},{"key":"6988_CR43","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/ki.2012.147","volume":"82","author":"SN Cox","year":"2012","unstructured":"Cox SN, Sallustio F, Serino G et al (2012) Activated innate immunity and the involvement of CX3CR1\u2013fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 82:548\u2013560. https:\/\/doi.org\/10.1038\/ki.2012.147","journal-title":"Kidney Int"},{"key":"6988_CR44","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.4049\/jimmunol.1402149","volume":"194","author":"DR Engel","year":"2015","unstructured":"Engel DR, Krause TA, Snelgrove SL et al (2015) Cx3cr1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages. J Immunol 194:1628\u20131638. https:\/\/doi.org\/10.4049\/jimmunol.1402149","journal-title":"J Immunol"},{"key":"6988_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2215\/cjn.01970211","volume":"7","author":"JA Moreno","year":"2012","unstructured":"Moreno JA, Mart\u00edn-Cleary C, Guti\u00e9rrez E (2012) Aki associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 7:175\u2013184. https:\/\/doi.org\/10.2215\/cjn.01970211","journal-title":"Clin J Am Soc Nephrol"},{"key":"6988_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW et al (2023) IgA nephropathy. Nat Rev Dis Primers 9:67. https:\/\/doi.org\/10.1038\/s41572-023-00476-9","journal-title":"Nat Rev Dis Primers"},{"key":"6988_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41581-019-0197-5","volume":"16","author":"RPL Van Swelm","year":"2020","unstructured":"Van Swelm RPL, Wetzels JFM, Swinkels DW (2020) The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 16:77\u201398. https:\/\/doi.org\/10.1038\/s41581-019-0197-5","journal-title":"Nat Rev Nephrol"},{"key":"6988_CR48","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si F-L et al (2024) Time-Varying Proteinuria and progression of IgA Nephropathy: A Cohort Study. Am J Kidney Dis 84:170-178.e171. https:\/\/doi.org\/10.1053\/j.ajkd.2023.12.016","journal-title":"Am J Kidney Dis"},{"key":"6988_CR49","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12104","volume":"76","author":"P Cravedi","year":"2013","unstructured":"Cravedi P, Remuzzi G (2013) Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 76:516\u2013523. https:\/\/doi.org\/10.1111\/bcp.12104","journal-title":"Br J Clin Pharmacol"},{"key":"6988_CR50","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2024) Clinical Practice Guideline for the Management of IgAN and IgAV. Kidney Disease: Improving Global Outcomes. https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf. Accessed 15 February 2025"},{"key":"6988_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10157-013-0849-x","volume":"18","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Matsuzaki K, Suzuki H et al (2014) Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18:481\u2013486. https:\/\/doi.org\/10.1007\/s10157-013-0849-x","journal-title":"Clin Exp Nephrol"},{"key":"6988_CR52","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10157-015-1105-3","volume":"19","author":"S Matsushita","year":"2015","unstructured":"Matsushita S, Ishikura K, Okamoto S et al (2015) Long-term morbidity of IgA nephropathy in children evaluated with newly proposed remission criteria in Japan. Clin Exp Nephrol 19:1149\u20131156. https:\/\/doi.org\/10.1007\/s10157-015-1105-3","journal-title":"Clin Exp Nephrol"},{"key":"6988_CR53","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00467-023-06259-4","volume":"39","author":"L Antonucci","year":"2024","unstructured":"Antonucci L, Fuiano L, Gargiulo A et al (2024) Childhood-onset IgA nephropathy: is long-term recovery possible? Pediatr Nephrol 39:1837\u20131846. https:\/\/doi.org\/10.1007\/s00467-023-06259-4","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06988-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06988-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:02:07Z","timestamp":1769608927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06988-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["6988"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06988-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Tongji Hospital Ethics Committee (Date13 December 2024\/NoTJ-IRB202412138).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was conducted using anonymized retrospective data. Informed consent was waived by the Ethics Committee of Tongji Hospital due to the non-interventional nature of the study and the use of de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}